Spark Therapeutics, a member of the Roche Group announced the appointment of Cynthia Pussinen as chief technical officer (CTO). Cynthia has more than 25 years of experience in the biopharma industry, leading teams in manufacturing, quality, supply chain, formulation development and process sciences. As CTO, she will oversee Spark’s manufacturing and technical operations, including pipeline process development, preclinical and clinical manufacturing, and the commercial manufacturing and distribution of LUXTURNA® (voretigene neparvovec-rzyl). Previously, Cynthia served as global vice president and general manager, Life Sciences and Specialty Chemicals, for Honeywell International Inc., where she developed and executed a comprehensive strategy designed for significant, sustained growth and innovation across multiple verticals including process automation and artificial intelligence (AI). Prior to her role at Honeywell, she was the executive vice president, Technical Development, Operations and Supply Chain for Actinium Pharmaceuticals Inc. Cynthia also worked at Ipsen Biosciences, the U.S. subsidiary of Ipsen, serving as president and, prior to that, vice president of Technical Operations and Development. She previously spent more than 18 years at Pfizer in a variety of roles including portfolio and project management, logistics and supply chain, pharmaceutical sciences and as a scientist in medicinal chemistry.